Stocks · News reference
Phase I trial in Germany will support treatment response monitoring for Kupando Therapeutics’ investigational immunotherapy using Latitude MRD testingNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Angiex is conducting a Phase I clinical trial of AGX101, an investigational TM4SF1-directed ND-ADC. AGX101 is designed to bind TM4SF1 and deliver a cytotoxic payload to TM4SF1-expressing tumor cells and tumor-associated
Read original at benzingaCitigroup analyst Brendan Digan maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $315 to $365.
Read original at benzingaPiper Sandler analyst David Westenberg maintains Natera (NASDAQ:NTRA) with a Overweight and raises the price target from $249 to $363.5.
Read original at benzingaStephens & Co. analyst Mason Carrico maintains Natera (NASDAQ:NTRA) with a Overweight and raises the price target from $305 to $350.
Read original at benzinga